

Viral exposure signature predicts hepatocellular carcinoma

July 13 2020



(HealthDay)—A viral exposure signature can predict hepatocellular

carcinoma (HCC) risk before clinical diagnosis among at-risk patients, according to a study published online June 10 in *Cell*.

Jinping Liu, Ph.D., of the National Cancer Institute in Bethesda, Maryland, and colleagues used a synthetic human virome technology, VirScan, to perform serological profiling of viral infection history in 899 individuals from a case-control study. A viral exposure signature was developed, and the results were validated in a longitudinal cohort with 173 at-risk patients with long-term follow-up for HCC development.

The researchers found that among at-risk individuals in the validation cohort, the viral exposure signature was significantly associated with HCC status (area under the curve, 0.91 at baseline and 0.98 at diagnosis). The signature was superior to alpha-fetoprotein and identified [cancer patients](#) before [clinical diagnosis](#).

"Together with existing [screening tests](#), the [new test](#) could play an important role in screening people who are at risk for developing HCC. It could help doctors find and treat HCC early," a coauthor said in a statement. "The method is relatively simple and inexpensive, and it only requires a small blood sample."

Several authors are listed as inventors on a U.S. patent application for the viral exposure signature for detection of early-stage HCC.

More information: [Abstract/Full Text](#)

Copyright © 2020 [HealthDay](#). All rights reserved.

Citation: Viral exposure signature predicts hepatocellular carcinoma (2020, July 13) retrieved 27 April 2024 from <https://medicalxpress.com/news/2020-07-viral-exposure-signature-hepatocellular-carcinoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.